Pro-Pharmaceuticals and Sanghyon Chemical Ink Historic Agency Agreement
July 09 2008 - 7:00AM
Business Wire
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company
developing proprietary polysaccharide-based therapeutic compounds
for the treatment of cancer and fibrosis, has entered into an
agency agreement with Sanghyon Chemical to represent the Company
with major pharmaceutical companies in Korea. Sanghyon Chemical
will provide for the registration of DAVANAT� with the Korean FDA
and marketing and sales support for the licensing and distribution
of DAVANAT� to treat cancer with chemotherapy drugs. �The
collaboration with Sanghyon Chemical is another step in the
realization of commercializing DAVANAT� on a regional basis,� said
Theodore Zucconi, Ph.D., President of Pro-Pharmaceuticals. �We
continue to pursue partnerships with regional distributors who
understand how to do business in their regions, as well as with
several large international pharmaceutical companies. Sanghyon is
an experienced partner that will enable us to penetrate a major
market such as Korea.� Sanghyon Chemical specializes in
pharmaceutical specialties and raw materials. Sanghyon imports raw
materials to Korea from companies such as Bristol-Myers Squibb
(NYSE: BMY) in the U.S. and Cognis in Australia. Sanghyon has
business relationships with the �Top Ten� Korean companies such as
LG Life Sciences, Dong-A, Yuhan, Daewoong Pharmaceutical Company,
SK Chemicals and Hanmi Pharmaceutical Company Ltd. �We will bring
partners to Pro-Pharmaceuticals who are interested in licensing
DAVANAT� for use with Irinotecan, 5-FU and other chemotherapy
drugs. The antineoplastic market in Korea is more than $600 million
per year and growing at about 25% annually. Korea represents a
great opportunity for Pro-Pharmaceuticals and we are happy to
represent them,� said Mr. Y.J. Kim, Sales Manager for Sanghyon
Chemical Corp. About DAVANAT� DAVANAT� is a proprietary
carbohydrate polymer that is administered with chemotherapies and
biologics to treat cancer. DAVANAT�'s mechanism of action is based
on binding to lectins. DAVANAT� targets specific lectin receptors
(�Galectins�) on cancer cells. Current research indicates that
Galectins affect cell development and play important roles in
cancer, including tumor cell survival, angiogenesis and tumor
metastasis. Pro-Pharmaceuticals, Inc. � Advancing Drugs Through
Glycoscience� Pro-Pharmaceuticals is engaged in the discovery,
development, and commercialization of carbohydrate-based, targeted
therapeutics for advanced treatment of cancer, liver, microbial,
and inflammatory diseases. Initially, the product pipeline is
focused on developing targeted therapeutic compounds to treat
cancer. The Company�s technology also is being used to treat liver
and kidney fibrosis. The Company is headquartered in Newton, Mass.
Additional information is available at www.pro-pharmaceuticals.com.
Pro-Pharmaceuticals, Inc. � Advancing Drugs Through Glycoscience�
Pro-Pharmaceuticals is a clinical stage pharmaceutical company
engaged in the discovery, development and commercialization of
carbohydrate-based, target therapeutic compounds for advanced
treatment of cancer, liver, microbial and inflammatory diseases.
The Company�s initial focus is the development of carbohydrate
polymers to treat cancer patients. DAVANAT�, the Company�s lead
product candidate, is a polysaccharide polymer that is in Phase II
trials for colorectal and biliary cancer. The Company�s technology
is also being used to develop new chemical entities to treat liver
and kidney fibrosis. The Company is headquartered in Newton, Mass.
Additional information is available at www.pro-pharmaceuticals.com.
DAVANAT� and Advancing Drugs Through Glycoscience are registered
trademarks of Pro-Pharmaceuticals. FORWARD LOOKING STATEMENTS: Any
statements in this news release about this or future financings,
expectations, plans and prospects for the Company, including
without limitation, statements containing the words �believes,�
�anticipates,� �plans,� �expects,� and similar expressions,
constitute forward-looking statements as defined in the �safe
harbor� provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding the expected closing of the private placement and the
anticipated use of proceeds. These forward-looking statements are
based on management�s current expectations and are subject to a
number of factors and uncertainties, which could cause actual
results to differ materially from those, described in such
statements. More information about those risks and uncertainties is
contained in the Company�s quarterly or annual report, Form 8-K and
in the Company�s other reports filed with the Securities and
Exchange Commission. While the Company anticipates that subsequent
events may cause the Company�s views to change, the Company
disclaims any obligation to update such forward-looking statements.
Pro (AMEX:PRW)
Historical Stock Chart
From May 2024 to Jun 2024
Pro (AMEX:PRW)
Historical Stock Chart
From Jun 2023 to Jun 2024